| 1. |
- Collins, M D, et al.
(author)
-
An unusual Streptococcus from human urine, Streptococcus urinalis sp. nov.
- 2000
-
In: International journal of systematic and evolutionary microbiology. - 1466-5026. ; 50 Pt 3, s. 1173-8
-
Journal article (peer-reviewed)abstract
- Biochemical, molecular chemical and molecular genetic studies were performed on an unknown Gram-positive, catalase-negative, chain-forming coccus isolated from the urine of a patient suffering from cystitis. Comparative 16S rRNA gene sequencing showed that the organism is a member of the 'pyogenic subgroup' of the genus Streptococcus and has a close affinity with Streptococcus pyogenes and Streptococcus canis. The unknown coccus was, however, readily distinguished from these species and other streptococci by biochemical tests and electrophoretic analysis of whole-cell proteins. Based on phenotypic and phylogenetic evidence, it is proposed that the unknown bacterium be classified as a new species of the genus Streptococcus, Streptococcus urinalis sp. nov. The type strain of Streptococcus urinalis is CCUG 41590T.
|
|
| 2. |
|
|
| 3. |
- van der Lely, A J, et al.
(author)
-
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
- 2001
-
In: Lancet (London, England). - 0140-6736. ; 358:9295, s. 1754-9
-
Journal article (peer-reviewed)abstract
- Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days.Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are excluded from the efficacy analysis.Mean serum IGF-1 concentrations fell by at least 50%: 467 mg/L (SE 24), 526 mg/L (29), and 523 mg/L (40) in patients treated for 6, 12 and 18 months, respectively (p<0.001), whereas growth hormone increased by 12.5 mg/L (2.1), 12.5 mg/L (3.0), and 14.2 mg/L (5.7) (p<0.001). Of the patients treated for 12 months or more, 87 of 90 (97%) achieved a normal serum IGF-1 concentration. In patients withdrawn from pegvisomant (n=45), serum growth hormone concentrations were 8.0 mg/L (2.5) at baseline, rose to 15.2 mg/L (2.4) on drug, and fell back within 30 days of withdrawal to 8.3 mg/L (2.7). Antibodies to growth hormone were detected in 27 (16.9%) of patients, but no tachyphylaxis was seen. Serum insulin and glucose concentrations were significantly decreased (p<0.05). Two patients experienced progressive growth of their pituitary tumours, and two other patients had increased alanine and asparate aminotransferase concentrations requiring withdrawal from treatment. Mean pituitary tumour volume in 131 patients followed for a mean of 11.46 months (0.70) decreased by 0.033 cm(3) (0.057; p=0.353).Pegvisomant is an effective medical treatment for acromegaly.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Jimenez, Camilo, et al.
(author)
-
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials
- 2008
-
In: European Journal of Endocrinology. - 1479-683X. ; 159:5, s. 517-523
-
Journal article (peer-reviewed)abstract
- Objective: We examined pituitary tumor volumes in patients treated with pegvisomant for 18 months or longer and in whom the tumors were monitored for at least 3 years. We present details on 9 of 304 patients in clinical trials with pegvisomant who experienced tumor growth within the first year of treatment. Method: Magnetic reonance images prior to start of pegvisomant and at last follow-up were examined in 43 patients (14% of participating patients). Twenty-nine had received prior radiation therapy (18% of irradiated patients and all but live received somatostatin analogs between periods of pegvisomant treatment. Results: At follow-up, the received tumor volume was 0.6 cc (range 0.0-19.7 ccl. in comparison with 1.6 cc (0.0-19.7 cc) at baseline (P<0.001). Twenty-five patients, of which 23 received radiation therapy, had tumor volume reduction therapy, had an increase in tumor volume from 1.61 to 1.93 cc. Of the nine patients with tumor growth, six had progressive growth before initiating pegvisomant. Two patients with stable tumors while on octreotide experienced enlargement after octreotide discontinuation but remained stable on long-term pegvisomant therapy. Conclusion: The present data indicate that pegvisomant does not promote tumor growth and suggest that the nine observed cases of tumor progression. which occured within 8 months after commencing pegvisomant, are likely rebound expansions after discontinuation of somatostatin analogs and/or the natural history of aggressively growing pituitary tumors. Continued long-term surveillance of tumor volume, particularly in non-irradiated patients is recommended.
|
|
| 7. |
- Collins, M D, et al.
(author)
-
Streptococcus ovis sp. nov., isolated from sheep.
- 2001
-
In: International journal of systematic and evolutionary microbiology. - 1466-5026. ; 51:Pt 3, s. 1147-50
-
Journal article (peer-reviewed)abstract
- Seven strains of an unknown Gram-positive catalase-negative chain-forming coccus-shaped organism isolated from clinical specimens from sheep were characterized by phenotypic and molecular taxonomic methods. Comparative 16S rRNA gene sequencing studies demonstrated that the bacterium represents a new sub-line within the genus Streptococcus. The unknown bacterium was readily distinguished from recognized streptococcal species by biochemical tests and electrophoretic analysis of whole-cell proteins. Based on phylogenetic and phenotypic evidence, it is proposed that the unknown bacterium be classified as Streptococcus ovis sp. nov. The type strain of Streptococcus ovis is CCUG 39485T (= LMG 19174T).
|
|
